Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 9,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Completed Phase 2 Interventional Results available

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

NCT00081159
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Doxorubicin hydrochloride, Goserelin acetate, Leuprolide acetate, Zoledronic acid, orchiectomy, strontium chloride Sr
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
4
States / cities
Orlando, Florida • Wichita, Kansas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam

NCT05386680
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
OAV101
Genetic
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Norfolk, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 22, 2026, 4:27 AM EDT
Active, not recruiting Not applicable Interventional

Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer

NCT06019988
View directory record Official record
Conditions
Breast Cancer, Social Determinants of Health (SDOH)
Interventions
Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

NCT03695185
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Ravagalimab 600 mg, Ravagalimab 300 mg
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Tucson, Arizona • Huntington Beach, California • Lakewood, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 22, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional Results available

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

NCT00968968
View directory record Official record
Conditions
Cancer
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
112
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 22, 2026, 4:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

NCT05230810
View directory record Official record
Conditions
HER2-positive Metastatic Breast Cancer
Interventions
Alpelisib, Tucatinib, Fulvestrant
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Carbon Monoxide Breath Sensor System Performance, Human Factors, and Usability Assessment Conducted in a Single Visit

NCT03148613
View directory record Official record
Conditions
Smoking, Tobacco
Interventions
Carbon Monoxide Breath Sensor System (COBSS), Bedfont - Micro+™ Smokerlyzer®
Device
Lead sponsor
David Utley, MD
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 22, 2026, 4:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

NCT00838578
View directory record Official record
Conditions
Colorectal Cancer
Interventions
KRN330, Irinotecan
Biological · Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 22, 2026, 4:27 AM EDT
Recruiting Phase 1 Interventional

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

NCT05698524
View directory record Official record
Conditions
Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma
Interventions
PCI 24781, Temozolomide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Phase 3 Interventional

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

NCT07214740
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
APL-2, Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Bakersfield, California • Oxnard, California • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

A Patient-centered Communication Tool (UR-GOAL) for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists

NCT04625413
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Behavioral: UR-GOAL communication tool
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

NCT01075113
View directory record Official record
Conditions
Liver Cancer
Interventions
sorafenib tosylate, vorinostat
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 22, 2026, 4:27 AM EDT
Terminated Not applicable Interventional Results available

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

NCT01156480
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
hydrocortisone, placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
0 Days to 6 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SweetMama: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women

NCT03240874
View directory record Official record
Conditions
Diabetes Mellitus in Pregnancy
Interventions
SweetMama Focus Groups, SweetMama Individual Testing, SweetMama Feasibility Testing - Pilot Randomized Trial
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 22, 2026, 4:27 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Healthy Cookie Study: Understanding How Healthy Cookies Affect Fat in the Blood,

NCT02841618
View directory record Official record
Conditions
Healthy Adults
Interventions
High Linoleic Acid Healthy Cookies, High Oleic Acid Healthy Cookies
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Not applicable Interventional

Increasing Treatment for Obesity Among Underserved Populations

NCT05666323
View directory record Official record
Conditions
Obesity
Interventions
Single Text Messaging (TM1), Patient Navigation (PN), Multiple Text Messaging (TM+)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Recommendations and Alerting for Delirium Alleviation in Real-Time (RADAR)

NCT04007523
View directory record Official record
Conditions
Delirium
Interventions
Family Support System, HELP Support System
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
70 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®

NCT03882424
View directory record Official record
Conditions
Healthy
Interventions
TRS003, China-approved Bevacizumab, US-licensed Avastin
Biological
Lead sponsor
Zhejiang Teruisi Pharmaceutical Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 22, 2026, 4:27 AM EDT
Recruiting Not applicable Interventional

Locomotor and Bladder Function in Individuals With Acute Spinal Cord Injury

NCT04879862
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Epidural stimulation + Stand Training, Epidural stimulation + Step Training, Epidural stimulation + Bladder Capacity Training, Epidural stimulation + Bladder Voiding Efficiency Training
Combination Product
Lead sponsor
Claudia Angeli
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 22, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

NCT06641180
View directory record Official record
Conditions
Influenza
Interventions
High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years to 64 Years
Enrollment
1,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 22, 2026, 4:27 AM EDT
Terminated Phase 2 Interventional Results available

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

NCT00602446
View directory record Official record
Conditions
Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
Interventions
deferasirox
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 22, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional

Avelumab/Gemcitabine in Sarcomatoid RCC

NCT03483883
View directory record Official record
Conditions
Metastatic sRCC
Interventions
Avelumab, Gemcitabine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 22, 2026, 4:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Developmental Framework For Linking Phonological And Morpho-syntactic Sequential Pattern Rules In DLD: Production

NCT04558541
View directory record Official record
Conditions
Developmental Language Disorder, Speech Sound Disorder, Specific Language Impairment
Interventions
Sensitivity to phonological rules, Sensitivity to semantic category cues.
Other
Lead sponsor
Father Flanagan's Boys' Home
Other
Eligibility
4 Years to 8 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 22, 2026, 4:27 AM EDT
Completed No phase listed Observational

Treatment De-Intensification and Residual HIV-1 in Youth

NCT00867854
View directory record Official record
Conditions
HIV-1, HIV Infections
Interventions
Blood draw
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 22, 2026, 4:27 AM EDT